Skip to main content
Equibles
MRNA logo

MRNA · Moderna, Inc.

Track MRNA — free

Use MRNA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MRNA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$142.77 -6.89 (-4.60%) At close · Aug 27
Market Cap
$58.75B
Shares
399.24M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$142.77 Open$144.18 Day$138.54–148.59 52W close$22.36–174.38 Avg vol 30d21.2M Short int52.8M · 13.2% float · 9.2d Short vol64% Last earningsJul 31, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 31

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 31, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +179%
      above
      Price vs 50-day avg +90%
      above
      RSI (14) 66
      neutral
      MACD trend Positive
      52-week position 79%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +147%
      trailing
      6-month return +172%
      trailing
      YTD return +384%
      this year
      Relative strength +157%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $75 › 200d $51 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +148 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      13.23% of float · ▲ +6.1% MoM · 9.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      789 holders — mid 3-yr range
      Squeeze score 95
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +4%
      Y/Y
      EPS growth +22%
      Y/Y
      Free cash flow $-2.1B
      Buyback $1.7B
      remaining
      Balance sheet $2.0B
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 192%
      annualized · 1-yr
      Max drawdown −34%
      past year
      ATR 10.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 5
      Latest guidance · from the 8-K filed Jul 31, 2026
      Selling, general and administrative expenses · 2026 $1B
      Research and development expenses · 2026 $2.9B
      Cost of sales · 2026 $1.7B
      Capital expenditures · 2026 $200M – $300M
      Year-end cash and investments · 2026 $4.7B – $5.2B
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2026
      Revenue · second quarter 2026 $50M – $100M
      Guided vs delivered · last 5 settled
      Projected revenue range 2025
      guided $1.5B – $2.2B
      $1.94B In line
      Net sales Q2
      guided $100M
      $241M Beat +141.0%
      Product sales full year 2023
      guided at least $6B
      $6.85B In line
      Sales 2024
      guided $4B
      $3.24B Miss −19.1%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +179% Bullish
      Price vs 50-day avg
      +90% Bullish
      RSI (14)
      66 Neutral
      MACD trend
      Positive Bullish
      52-week position
      79% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $75 › 200d $51 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +148 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      13.23% of float · ▲ +6.1% MoM · 9.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      789 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $22 Now $143 · 79% Range high $174
      vs 200-day avg +179% vs 50-day avg +90%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      MRNA
      Moderna, Inc.
      this stock
      		$58.75B +384.1% +4.3% — 13.2%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +4.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +25.9% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      789
      % held
      90.3%
      Net QoQ
      -8.5M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      641
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      52.8M
      Days to cover
      9.2d
      Change
      +3.0M sh
      View
      Short Volume
      Short vol %
      64%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      136.0K
      Value
      $7.9M
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      43.5%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Rob Bresnahan
      Amount
      $1.0K–$15.0K
      Traded
      Apr 8, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $1.9B
      Net income (FY)
      $-2.8B
      EPS diluted
      $-7.26
      View
      Buybacks
      Authorized
      $3.0B
      Remaining
      $1.7B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 31, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $29.0M
      Shares
      499.2K
      Filed
      Aug 5, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 31, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      MRNA +7.1% +146.5% +171.8% +160.4% +384.1%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +6.0% +142.5% +157.2% +157.2% +371.1%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $3.00B
      Spent (derived)
      $1.30B
      Remaining
      $1.70B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1682852 CUSIP 60770K107 13F (30d) 573 filings 569 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)